Showing results (61-70 of 554) with videos related to
Sort By:
Pageof 56
Expert Opinion on Emerging Drugs|March 30, 2018
PARP inhibitors for homologous recombination-deficient prostate cancerEric S Christenson, Emmanuel S AntonarakisCurrent Urology Reports|April 29, 2010
Update: immunological strategies for prostate cancerCharles G Drake, Emmanuel S AntonarakisCancer Metastasis Reviews|January 10, 2014
Growth factor and signaling pathways and their relevance to prostate cancer therapeuticsJocelyn L Wozney, Emmanuel S AntonarakisTherapeutic Advances in Urology|August 2, 2012
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is bornMichael T Schweizer, Emmanuel S AntonarakisDrug Design, Development and Therapy|August 4, 2016
Galeterone for the treatment of advanced prostate cancer: the evidence to dateDiogo A Bastos, Emmanuel S AntonarakisExpert Opinion on Pharmacotherapy|June 13, 2015
Androgen pathway resistance in prostate cancer and therapeutic implicationsBenjamin L Maughan, Emmanuel S AntonarakisScience Translational Medicine|November 6, 2015
Liquid biopsy: Clues on prostate cancer drug resistanceMichael T Schweizer, Emmanuel S AntonarakisExpert Review of Clinical Pharmacology|April 12, 2018
PD-1/PD-L1 pathway inhibitors in advanced prostate cancerPedro Isaacsson Velho, Emmanuel S AntonarakisExpert Opinion on Pharmacotherapy|April 8, 2021
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancerBenjamin L Maughan, Emmanuel S AntonarakisProstate Cancer and Prostatic Diseases|May 18, 2011
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancerE S Antonarakis, A J ArmstrongPageof 56